25 January 2017

Prospero House, 241 Borough High Street, London

Draft Agenda

The meeting will start promptly at 10am and is expected to finish at approximately 6pm.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 2 November 2016 – Part 1 only (open session)
  6. Appraisal of eluxadoline for treating irritable bowel syndrome with diarrhoea [ID870]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by Chair, Dr Amanda Adler – Part 1 only (open session)
    • 6.3. Presentation by the Lead Team – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of cabozantinib for previously treated advanced renal cell carcinoma [ID931]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by Chair, Dr Amanda Adler – Part 1 only (open session)
    • 7.3. Presentation by the Lead Team – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of cetuximab and panitumumab for previously untreated  metastatic colorectal cancer [ID794]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 8.3. Presentation by Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  9. Appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904]
    • 9.1. Declarations of interest - Part 1 only (open session)
    • 9.2. Introduction by Vice Chair, Dr Sanjeev Patel - Part 1 only (open session)
    • 9.3. Presentation by Dr Sanjeev Patel - Part 1 and part 2 (open and closed session)
    • 9.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  10. Appraisal of daclizumab for treating relapsing-remitting multiple sclerosis [ID827]
    • 10.1. Declarations of interest - Part 2 only (closed session)
    • 10.2. Introduction by Chair, Dr Amanda Adler - Part 2 only (closed session)
    • 10.3. Presentation by Dr Amanda Adler - Part 2 only (closed session)
    • 10.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on 22 February 2017, at the NICE offices, 10 Spring Gardens, London.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on 11 January 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Josh South.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 19 December 2016 to 11 January 2017
Registration is closed.